NASDAQ:IKT

Inhibikase Therapeutics Stock News

Healthcare > Biotechnology

Buy IKT

*Your capital is at risk

$1.70

-0.0100 (-0.585%)

At Close: Jun 02, 2026

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer

08:01am, Monday, 04'th Jan 2021

ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related diso

Inhibikase Therapeutics Announces Closing of Initial Public Offering

10:33am, Monday, 28'th Dec 2020

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related d

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by